What Happened
- Union Health Minister J.P. Nadda formally launched the indigenously manufactured Tetanus and Adult Diphtheria (Td) vaccine at the Central Research Institute (CRI), Kasauli, Himachal Pradesh on February 21, 2026
- The launch marks the formal integration of the Td vaccine into India's Universal Immunization Programme (UIP), replacing the older Tetanus Toxoid (TT) vaccine — a change recommended by WHO since 2006
- CRI Kasauli is the first central government institution to manufacture vaccines under Good Manufacturing Practices (GMP) standards; all required developmental studies and regulatory approvals (including Central Drugs Laboratory clearance) have been completed
- CRI will supply 55 lakh (5.5 million) doses of the Td vaccine to the UIP by April 2026, with production capacity set to expand
- The indigenously manufactured Td vaccine reduces India's dependence on external vaccine supplies and aligns with the broader "Atmanirbhar Bharat" health security agenda
Static Topic Bridges
Tetanus and Diphtheria — Disease Burden and Vaccine Science
Tetanus (lockjaw) is caused by the bacterium Clostridium tetani, which produces a neurotoxin causing severe muscle spasms. Diphtheria is caused by Corynebacterium diphtheriae, producing a toxin that affects the throat and other organs. Both are vaccine-preventable diseases included in India's immunisation schedule for decades.
- Tetanus Toxoid (TT) vaccine: Older formulation; protects only against tetanus; used in India's immunisation programme for decades
- Td vaccine: Combined formulation — protects against both tetanus and diphtheria; uses a reduced-antigen (lower dose) diphtheria component (hence "adult diphtheria," distinct from the full diphtheria component in childhood DTP/Pentavalent vaccines)
- WHO recommendation: WHO recommended the switch from TT to Td for adolescent and antenatal immunisation in 2006; India has now formalised this transition
- Vaccination schedule for Td (UIP): Adolescents at 10 and 16 years of age; pregnant women (replaces the earlier TT schedule for these groups)
- No change in target population or schedule — Td simply replaces TT in the same immunisation slots
- DTP (Diphtheria-Tetanus-Pertussis) and Pentavalent vaccines continue to cover infants (6 weeks, 10 weeks, 14 weeks, with booster at 16-24 months)
Connection to this news: The shift from TT to Td aligns India's immunisation programme with WHO's global guidance and provides broader protection (adding diphtheria coverage) to adolescents and pregnant women who previously received only tetanus protection.
Universal Immunization Programme (UIP) — Architecture and Governance
India's Universal Immunization Programme is one of the largest public health initiatives in the world, covering approximately 26 million newborns and 30 million pregnant women annually. It is administered under the National Health Mission (NHM).
- UIP launched: 1985 (as part of the Expanded Programme on Immunization, which started in 1978); made universal in 1990
- Nodal ministry: Ministry of Health and Family Welfare (MoHFW)
- Implementing framework: National Health Mission (NHM), established under the National Rural Health Mission (2005), expanded to urban areas in 2013
- Vaccines under UIP (current): BCG, Hepatitis B, Oral Polio Vaccine (OPV), Inactivated Polio Vaccine (IPV), Pentavalent (DTP+HepB+Hib), Pneumococcal Conjugate Vaccine (PCV), Rotavirus vaccine, Measles-Rubella (MR), Japanese Encephalitis (in endemic districts), Td (now replacing TT for adolescents and pregnant women)
- Mission Indradhanush (2014): Intensified immunisation drive targeting zero-dose and low-coverage children; Mission Indradhanush 4.0 (2022-23) extended coverage
- India's immunisation coverage: Full immunisation rate approximately 76% (NFHS-5, 2019-21) — still below 90% target
Connection to this news: The Td vaccine's integration into UIP is a programme upgrade within the existing architecture — CRI's supply of 55 lakh doses by April 2026 will be absorbed into the existing cold chain and delivery mechanism with no structural changes.
Central Research Institute (CRI), Kasauli — India's Oldest Vaccine Institution
CRI Kasauli is a subordinate office under the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare. It is one of India's oldest and most historically significant public health institutions.
- Established: May 3, 1905 (as Pasteur Institute for India, by Sir David Semple); land donated by Ranbir Singh, son of Maharaja Rajinder Singh of Patiala
- Location: Kasauli, Himachal Pradesh (altitude approximately 1,800 m above sea level)
- Historical significance: Pioneer in smallpox, cholera, and typhoid vaccine production; contributed critically to troop immunisation during World War II
- Current mandate: Research, manufacture of vaccines and antisera, human resource development, national referral centre for public health
- Products: DPT group of vaccines (including DTP and Td), antisera (Anti-Snake Venom, Anti-Rabies, Diphtheria Antitoxin, Tetanus Antitoxin)
- GMP compliance: First central government institute to achieve cGMP (current Good Manufacturing Practices) compliant infrastructure for vaccine production — now validated through the Td vaccine licensure
Connection to this news: CRI's manufacturing of the Td vaccine under GMP standards is a significant capability milestone — it demonstrates that India's public sector vaccine manufacturing capacity extends to modern regulatory-grade production, reducing dependence on private sector or imported formulations.
Atmanirbhar Bharat in Pharmaceuticals and Vaccines
India is the world's largest supplier of vaccines by volume (approximately 60% of global vaccine supply, predominantly through Serum Institute, Bharat Biotech, and others). However, the domestic public sector vaccine manufacturing has lagged behind. The Td vaccine launch at CRI represents a reinvigoration of public sector capacity.
- India's vaccine manufacturing capacity (private sector): Serum Institute of India (Pune) — world's largest vaccine manufacturer by volume; Bharat Biotech (Hyderabad) — Covaxin, Rotavac; Biological E (Hyderabad); Indian Immunologicals (Hyderabad)
- COVID-19 vaccine manufacturing: India manufactured and supplied approximately 1.8 billion doses globally — demonstrated scale capability
- Vaccine supply under UIP: Government procures centrally through a pooled procurement mechanism; price negotiations with manufacturers; free to beneficiaries at government facilities
- National Vaccine Policy (2011): Framework for vaccine development, manufacturing, procurement, and delivery in India
- PLI Scheme for Pharmaceuticals (2021): Incentivises domestic manufacturing of bulk drugs and medical devices including vaccines; ₹15,000 crore over 6 years
- GMP standards: Mandatory for WHO prequalification — vaccines manufactured under GMP can be exported or procured by UN agencies (UNICEF, PAHO)
Connection to this news: CRI's GMP-compliant Td vaccine is not just a domestic supply achievement — it potentially opens pathways for CRI to supply to international markets, including UNICEF-procured programmes, under WHO prequalification.
Key Facts & Data
- CRI Kasauli established: May 3, 1905
- Td vaccine target supply to UIP: 55 lakh (5.5 million) doses by April 2026
- Td vaccine schedule in UIP: Adolescents at 10 and 16 years; pregnant women (replaces TT in same slots)
- WHO recommendation to switch TT → Td: 2006 (India formally implemented 2026)
- UIP launched: 1985 (made universal 1990); approximately 26 million newborns covered annually
- India's full immunisation coverage: approximately 76% (NFHS-5, 2019-21)
- CRI: First central government institute with cGMP-compliant vaccine infrastructure
- CRI products: DPT vaccines, antisera (ARS, ATS, DATS, TATS)
- India's share of global vaccine supply: approximately 60% by volume
- PLI Scheme for Pharmaceuticals: ₹15,000 crore over 6 years (2021)